Although the use of SGLT2-i or GLP-1 RA was slightly greater in Hispanic or Latino people than in non-Hispanic White persons, barely one-tenth of all ethnic groups with DM are on these newer therapies. This evidence concerns the gene SLC5A2 and diabetes mellitus.